Literature DB >> 23959774

Malignant mesothelioma: development to therapy.

Joyce K Thompson1, Catherine M Westbom, Arti Shukla.   

Abstract

Malignant mesothelioma (MM) is an aggressive cancer of the mesothelium caused by asbestos. Asbestos use has been reduced but not completely stopped. In addition, natural or man-made disasters will continue to dislodge asbestos from old buildings into the atmosphere and as long as respirable asbestos is available, MM will continue to be a threat. Due to the long latency period of MM development, it would still take decades to eradicate this disease if asbestos was completely removed from our lives today. Therefore, there is a need for researchers and clinicians to work together to understand this deadly disease and find a solution for early diagnosis and treatment. This article focuses on developmental mechanisms as well as current therapies available for MM.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  ASBESTOS; INFLAMMATION; MALIGNANT MESOTHELIOMA; MESOTHELIUM

Mesh:

Substances:

Year:  2014        PMID: 23959774      PMCID: PMC3856563          DOI: 10.1002/jcb.24642

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  58 in total

1.  Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province.

Authors:  J C WAGNER; C A SLEGGS; P MARCHAND
Journal:  Br J Ind Med       Date:  1960-10

2.  Podoplanin overexpression in human mesothelioma cell lines enhances the tumorigenic phenotype.

Authors:  Ei Yamaki; Toshiki Yajima; Takayuki Kosaka; Akira Mogi; Shigebumi Tanaka; Hiroyuki Kuwano
Journal:  Oncol Rep       Date:  2013-01-04       Impact factor: 3.906

3.  Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair.

Authors:  Kushtrim Kryeziu; Ute Jungwirth; Mir Alireza Hoda; Franziska Ferk; Siegfried Knasmüller; Claudia Karnthaler-Benbakka; Christian R Kowol; Walter Berger; Petra Heffeter
Journal:  Mol Cancer Ther       Date:  2013-04-02       Impact factor: 6.261

4.  Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers.

Authors:  Michael K Felten; Khaled Khatab; Lars Knoll; Thomas Schettgen; Hendrik Müller-Berndorff; Thomas Kraus
Journal:  Int Arch Occup Environ Health       Date:  2013-02-20       Impact factor: 3.015

5.  Alterations in gene expression in human mesothelial cells correlate with mineral pathogenicity.

Authors:  Arti Shukla; Maximilian B MacPherson; Jedd Hillegass; Maria E Ramos-Nino; Vlada Alexeeva; Pamela M Vacek; Jeffrey P Bond; Harvey I Pass; Chad Steele; Brooke T Mossman
Journal:  Am J Respir Cell Mol Biol       Date:  2008-12-18       Impact factor: 6.914

6.  SV40-induced expression of calretinin protects mesothelial cells from asbestos cytotoxicity and may be a key factor contributing to mesothelioma pathogenesis.

Authors:  Thomas Henzi; Walter-Vincent Blum; Martine Pfefferli; Tadeusz J Kawecki; Valerie Salicio; Beat Schwaller
Journal:  Am J Pathol       Date:  2009-05-12       Impact factor: 4.307

7.  US mesothelioma patterns 1973-2002: indicators of change and insights into background rates.

Authors:  Mary Jane Teta; Pamela J Mink; Edmund Lau; Bonnielin K Sceurman; Edward D Foster
Journal:  Eur J Cancer Prev       Date:  2008-11       Impact factor: 2.497

8.  A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.

Authors:  John E Weldon; Laiman Xiang; Jingli Zhang; Richard Beers; Dawn A Walker; Masanori Onda; Raffit Hassan; Ira Pastan
Journal:  Mol Cancer Ther       Date:  2012-11-06       Impact factor: 6.261

9.  Gene expression profiles in asbestos-exposed epithelial and mesothelial lung cell lines.

Authors:  Penny Nymark; Pamela M Lindholm; Mikko V Korpela; Leo Lahti; Salla Ruosaari; Samuel Kaski; Jaakko Hollmén; Sisko Anttila; Vuokko L Kinnula; Sakari Knuutila
Journal:  BMC Genomics       Date:  2007-03-01       Impact factor: 3.969

10.  EphB4 as a therapeutic target in mesothelioma.

Authors:  Ren Liu; Benjamin D Ferguson; Yue Zhou; Kranthi Naga; Ravi Salgia; Parkash S Gill; Valery Krasnoperov
Journal:  BMC Cancer       Date:  2013-05-30       Impact factor: 4.430

View more
  7 in total

1.  Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials.

Authors:  Danjie Zhang; Ming-Hui Chen; Joseph G Ibrahim; Mark E Boye; Ping Wang; Wei Shen
Journal:  Stat Med       Date:  2014-07-20       Impact factor: 2.373

2.  Differential Susceptibility of Human Pleural and Peritoneal Mesothelial Cells to Asbestos Exposure.

Authors:  Julie Dragon; Joyce Thompson; Maximilian MacPherson; Arti Shukla
Journal:  J Cell Biochem       Date:  2015-08       Impact factor: 4.429

3.  Development of Optimized, Inhalable, Gemcitabine-Loaded Gelatin Nanocarriers for Lung Cancer.

Authors:  Susanne R Youngren-Ortiz; David B Hill; Peter R Hoffmann; Kenneth R Morris; Edward G Barrett; M Gregory Forest; Mahavir B Chougule
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2017-03-09       Impact factor: 2.849

4.  Asbestos-Induced Mesothelial to Fibroblastic Transition Is Modulated by the Inflammasome.

Authors:  Joyce K Thompson; Maximilian B MacPherson; Stacie L Beuschel; Arti Shukla
Journal:  Am J Pathol       Date:  2017-01-03       Impact factor: 4.307

5.  Bayesian Model Assessment in Joint Modeling of Longitudinal and Survival Data with Applications to Cancer Clinical Trials.

Authors:  Danjie Zhang; Ming-Hui Chen; Joseph G Ibrahim; Mark E Boye; Wei Shen
Journal:  J Comput Graph Stat       Date:  2017-02-16       Impact factor: 2.302

6.  Dual preventive benefits of iron elimination by desferal in asbestos-induced mesothelial carcinogenesis.

Authors:  Li Jiang; Shan-Hwu Chew; Kosuke Nakamura; Yuuki Ohara; Shinya Akatsuka; Shinya Toyokuni
Journal:  Cancer Sci       Date:  2016-06-13       Impact factor: 6.716

7.  Extracellular signal regulated kinase 5 and inflammasome in progression of mesothelioma.

Authors:  Joyce K Thompson; Anurag Shukla; Alan L Leggett; Phillip B Munson; Jill M Miller; Maximilian B MacPherson; Stacie L Beuschel; Harvey I Pass; Arti Shukla
Journal:  Oncotarget       Date:  2017-12-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.